Blog
RSS FeedPosted by Michael Wonder on 30 Sep 2015
NICE rejects Celgene's Otezla for psoriasis
30 September 2015 - Patients with chronic plaque psoriasis are being prevented from routinely accessing Celgene’s Otezla on the National Health ...
Posted by Michael Wonder on 24 Sep 2015
NICE says yes to new class of drug for adults with leukaemia
24 September 2015 - NICE has issued final draft guidance which recommends that idelalisib (marketed as Zydelig by Gilead Sciences) should ...
Posted by Michael Wonder on 24 Sep 2015
NICE recommends edoxaban tosylate (Lixiana) for preventing potentially fatal blood clots in people with atrial fibrillation
23 September 2015 - In final guidance published today NICE has recommended the anti-blood clotting drug edoxaban (Lixiana, Daiichi Sankyo) as ...
Posted by Michael Wonder on 23 Sep 2015
Final NICE yes for Daiichi's bloodthinner Lixiana
23 September 2015 - The National Institute for Health and Care Excellence has issued final guidance recommending Daiichi Sankyo’s bloodthinner Lixiana ...
Posted by Michael Wonder on 17 Sep 2015
Pancreatic cancer patients denied life-extending drug by spending watchdog
17 September 2015 - The only new pancreatic cancer drug licensed for 17 years will not be funded in England, the ...
Posted by Michael Wonder on 17 Sep 2015
NICE publishes final draft guidance on nab-paclitaxel (Abraxane) for pancreatic cancer
17 September 2015 - The cost of using nab-paclitaxel (marketed as Abraxane by Celgene) to treat pancreatic cancer is not justified ...
Posted by Michael Wonder on 16 Sep 2015
NICE proposes further research for Dupuytren’s contracture treatment
16 September 2015 - NICE has today confirmed its previous final draft guidance not to recommend collagenase clostridium histolyticum (Xiapex, Swedish ...
Posted by Michael Wonder on 15 Sep 2015
NICE 'no' for Novartis' Farydak a blow for multiple myeloma patients
15 September 2015 - UK patients with myeloma have been dealt yet another blow after cost regulators issued a preliminary rejection ...
Posted by Michael Wonder on 15 Sep 2015
Early NICE rejection for Lilly's gastric cancer drug Cyramza
15 September 2015 - It is looking unlikely that patients with gastric cancer will get routine access to Eli Lilly’s Cyramza ...
Posted by Michael Wonder on 14 Sep 2015
NICE draft guidance recommends treatments for types of arthritis that affect the spine
11 September 2015 - In final draft guidance published today NICE has recommended adalimumab (Humira, AbbVie), etanercept (Enbrel, Pfizer), infliximab (Remicade, ...
Posted by Michael Wonder on 11 Sep 2015
NICE nod for BI's lung-scarring drug Ofev
11 September 2015 - UK patients with idiopathic pulmonary fibrosis (IPF) could soon get routine access to the first targeted therapy ...
Posted by Michael Wonder on 11 Sep 2015
NICE draft guidance recommends treatments for types of arthritis that affect the spine
11 September 2015 - In final draft guidance published today NICE has recommended adalimumab (Humira, AbbVie), etanercept (Enbrel, Pfizer), infliximab (Remicade, ...
Posted by Michael Wonder on 07 Sep 2015
NICE recommends pembrolizumab for advanced skin cancer in final draft guidance
7 September 2015 - NICE recommends that the drug pembrolizumab (also called Keytruda and manufactured by Merck, Sharp & Dohme) is ...
Posted by Michael Wonder on 04 Sep 2015
NICE joins project to make development of new treatments more efficient
4 September 2015 - Called the Accelerated Development of Appropriate Patient Therapies (ADAPT SMART), and funded by the EU Innovative Medicines ...
Posted by Michael Wonder on 03 Sep 2015
NICE issues draft guidance on apremilast for psoriatic arthritis
3 September 2015 - NICE has published final draft guidance today which does not recommend apremilast (Otezla, Celgene) for adults with ...